HROW HARROW, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1360214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.3%
TTM net income YoY-471.2%
TTM EPS YoY-484.6%
Revenue 3-yr CAGR38.5%
Net income 3-yr CAGR—
Margins
Gross margin73.5%
Operating margin-2.0%
Net margin-9.4%
FCF margin-6.7%
EBITDA margin-1.4%
Returns
ROE-74.8%
ROA-7.1%
ROIC (approx.)-3.5%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets93.5%
Debt / equity0.00x
Current ratio2.29x
Interest coverage-0.26x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $99.30M | $70.66M | $44.20M | $89.09M | $71.64M | $63.74M | $47.83M | $66.83M |
| Cost of revenue | $24.39M | $20.30M | $17.16M | $18.47M | $17.71M | $16.23M | $15.52M | $14.13M |
| Gross profit | $74.90M | $50.36M | $27.05M | $70.62M | $53.93M | $47.51M | $32.31M | $52.70M |
| R&D expense | $10.29M | $8.07M | $5.89M | $11.72M | $3.32M | $2.87M | $3.03M | $4.75M |
| SG&A expense | $53.15M | $53.30M | $43.23M | $43.31M | $35.86M | $33.23M | $40.51M | $34.79M |
| Operating income | $11.47M | -$11.01M | -$22.08M | $15.59M | $14.75M | $11.41M | -$11.23M | $12.90M |
| Interest expense | $6.21M | $6.26M | $5.50M | $5.19M | $6.04M | $6.41M | $6.55M | $6.38M |
| Pretax income | $10.26M | -$17.27M | -$27.58M | $10.40M | $1.02M | $5.00M | -$17.78M | $6.26M |
| Income tax | $506,000 | $0 | $25,000 | $3.77M | $0 | $0 | — | -$514,000 |
| Net income | $9.76M | -$17.27M | -$27.60M | $6.63M | $1.02M | $5.00M | -$17.78M | $6.78M |
| EBITDA | $11.92M | -$10.55M | -$21.62M | $16.05M | $15.07M | $11.76M | -$10.77M | $13.37M |
| EPS (basic) | 0.26 | -0.46 | -0.74 | — | 0.03 | 0.14 | -0.50 | — |
| EPS (diluted) | 0.25 | -0.46 | -0.74 | — | 0.03 | 0.13 | -0.50 | — |
| Weighted avg. shares (diluted) | 38.53M | 37.35M | 37.23M | — | 38.88M | 38.85M | 35.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $75.34M | $83.89M | $94.64M | $72.93M | $74.29M | $52.96M | $66.73M | $47.25M |
| Receivables | $155.31M | $118.56M | $101.26M | $110.89M | $77.60M | $78.82M | $77.06M | $116.37M |
| Inventory | $19.22M | $16.91M | $16.50M | $13.52M | $12.83M | $11.55M | $10.72M | $10.70M |
| Current assets | $261.33M | $229.31M | $226.38M | $211.75M | $177.60M | $154.89M | $169.53M | $189.65M |
| PP&E, net | $2.82M | $2.96M | $3.13M | $3.26M | $3.38M | $3.51M | $3.57M | $3.73M |
| Goodwill | $332,000 | $332,000 | $332,000 | $332,000 | $332,000 | $332,000 | $332,000 | $332,000 |
| Intangibles | $170.03M | $175.57M | $181.05M | $175.17M | $172.46M | $176.67M | $180.76M | $184.95M |
| Total assets | $443.02M | $416.82M | $419.54M | $399.48M | $363.07M | $345.03M | $364.16M | $388.97M |
| Current liabilities | $114.22M | $102.17M | $91.44M | $96.30M | $65.40M | $248.88M | $186.99M | $91.34M |
| Long-term debt | — | — | $300.00M | $250.00M | $347.24M | $250.62M | $256.91M | $262.74M |
| Total debt | — | — | $300.00M | $250.00M | $347.24M | $250.62M | $256.91M | $262.74M |
| Total liabilities | $414.19M | $401.97M | $391.19M | $347.39M | $316.41M | $295.73M | $308.07M | $319.67M |
| Shareholders' equity | $29.19M | $15.20M | $28.71M | $52.45M | $47.02M | $49.65M | $56.45M | $69.65M |
| Net debt | — | — | $205.36M | $177.07M | $272.95M | $197.66M | $190.19M | $215.49M |
| Shares outstanding | 37.52M | 37.48M | 37.27M | 37.23M | 37.03M | 36.71M | 35.65M | 35.62M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.62M | -$9.76M | -$8.99M | $8.41M | $16.59M | -$803,000 | $19.67M | -$17.78M |
| Capital expenditure | $375,000 | $491,000 | $194,000 | $341,000 | $210,000 | $166,000 | $170,000 | $555,000 |
| Free cash flow | -$8.99M | -$10.25M | -$9.19M | $8.07M | $16.38M | -$969,000 | $19.50M | -$18.33M |
| Investing cash flow | -$406,000 | -$534,000 | -$18.20M | -$4.73M | -$225,000 | -$293,000 | -$212,000 | -$37.56M |
| Financing cash flow | $469,000 | -$466,000 | $48.91M | -$5.04M | $4.96M | -$12.67M | $23,000 | $29.98M |
| Depreciation & amortization | $446,000 | $460,000 | $455,000 | $464,000 | $326,000 | $347,000 | $465,000 | $468,000 |
| Stock-based compensation | $3.73M | $3.79M | $3.84M | $3.80M | $3.27M | $875,000 | $4.56M | $4.79M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.